Journal
LEUKEMIA & LYMPHOMA
Volume 51, Issue 12, Pages 2159-2170Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2010.525725
Keywords
Myeloma; MGUS; smoldering myeloma; prognosis; molecular imaging; molecular profiling
Categories
Funding
- National Cancer Institute of the National Institutes of Health
Ask authors/readers for more resources
Multiple myeloma (MM) is a malignant plasma cell dyscrasia localized in the bone marrow. Recent studies have shown that MM is preceded in virtually all cases by a premalignant state called monoclonal gammopathy of undetermined significance (MGUS). This review focuses on non-IgM MGUS and its progression to MM. Although certain clinical markers of MGUS progression have been identified, it currently is not possible to accurately determine individual risk of progression. This review focuses on the various biologic and molecular markers that could be used to determine the risk of MM progression. A better understanding of the pathogenesis will allow us to define the biological high-risk precursor disease and, ultimately, to develop early intervention strategies designed to delay and prevent full-blown MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available